Bullish indicating open at $55-$60, IPO prices at $37
Daniel Virnich, the Chief Executive Officer of Oncology Institute, Inc. (NASDAQ:TOI), recently acquired additional shares in the company. According to a recent SEC filing, Virnich purchased 22,640 shares of common stock on March 26, 2025, at an average price of $1.0417 per share, totaling approximately $23,584. The timing appears strategic, as InvestingPro data shows TOI has delivered an impressive 259% return year-to-date, with analysts maintaining a Strong Buy consensus and a $2 price target.
This acquisition was part of a private placement transaction, where Virnich also acquired common warrants. The transaction was approved by the company’s board and deemed exempt under Rule 16b-3 of the Securities Exchange Act. Following this transaction, Virnich’s direct ownership stands at 724,363 shares. With a market capitalization of $86 million and an overall Financial Health score rated as "GOOD" by InvestingPro, which offers 8 additional key insights about TOI’s valuation and growth prospects in its comprehensive Pro Research Report.
In other recent news, The Oncology Institute reported its Q4 2024 financial results, revealing a net loss despite strategic growth initiatives. The company missed both earnings per share (EPS) and revenue forecasts, with an actual EPS of -$0.14 against a forecast of -$0.08, and revenue at $100.3 million, below the expected $109.15 million. Despite these figures, the Oncology Institute highlighted a 17% year-over-year increase in quarterly revenue and a 21.3% increase in full-year revenue to $393 million. The company also noted a decrease in gross profit by 9.4% for the full year. Looking forward, the Oncology Institute projects 2025 revenue between $460 million and $480 million, with expectations to achieve profitability by the end of 2025. Strategic expansions, particularly in Florida, and new service contracts were emphasized as growth drivers. The company also successfully restructured its financial agreements, including a $20 million principal pay down, and announced a $16.5 million private placement of common equity. Analyst firm B. Riley inquired about future growth drivers, to which the company responded with plans to leverage new capitation contracts and organic growth in key markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.